{"id":595,"date":"2025-07-08T18:07:19","date_gmt":"2025-07-08T16:07:19","guid":{"rendered":"https:\/\/sinfatin.com\/?page_id=595"},"modified":"2026-11-03T13:35:48","modified_gmt":"2026-11-03T12:35:48","slug":"desarrollo-clinico-de-rimonabant","status":"publish","type":"page","link":"https:\/\/sinfatin.com\/en\/clinical-development-of-rimonabant\/","title":{"rendered":"Rimonabant"},"content":{"rendered":"<div data-elementor-type=\"wp-page\" data-elementor-id=\"595\" class=\"elementor elementor-595\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4ae760d e-con-full e-flex e-con e-parent\" data-id=\"4ae760d\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;position&quot;:&quot;fixed&quot;}\">\n\t\t<div class=\"elementor-element elementor-element-5feb67a9 e-con-full e-flex e-con e-child\" data-id=\"5feb67a9\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-48fcf608 elementor-widget elementor-widget-progress-tracker\" data-id=\"48fcf608\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;direction&quot;:&quot;ltr&quot;,&quot;type&quot;:&quot;horizontal&quot;,&quot;relative_to&quot;:&quot;entire_page&quot;}\" data-widget_type=\"progress-tracker.default\">\n\t\t\t\t\t\n\t\t<div class=\"elementor-scrolling-tracker elementor-scrolling-tracker-horizontal elementor-scrolling-tracker-alignment-\">\n\t\t\t\t\t\t<div class=\"current-progress\">\n\t\t\t\t\t<div class=\"current-progress-percentage\"><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-5cc332f3 e-flex e-con-boxed e-con e-parent\" data-id=\"5cc332f3\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-1eb0f931 elementor-widget-mobile__width-inherit elementor-widget elementor-widget-heading\" data-id=\"1eb0f931\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Clinical development of Rimonabant<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-19e7d76e elementor-widget elementor-widget-breadcrumbs\" data-id=\"19e7d76e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"breadcrumbs.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<nav aria-label=\"breadcrumbs\" class=\"rank-math-breadcrumb\"><p><span class=\"last\">Start<\/span><\/p><\/nav>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-6fe49cd e-flex e-con-boxed e-con e-parent\" data-id=\"6fe49cd\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-9180261 elementor-widget elementor-widget-heading\" data-id=\"9180261\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">The European Commission grants orphan drug designation to SFT-1 (rimonabant), from Sinfatin SL, for the treatment of spinal cord injuries<\/h2>\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-501e070 e-flex e-con-boxed e-con e-parent\" data-id=\"501e070\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-33265da elementor-widget elementor-widget-text-editor\" data-id=\"33265da\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>At Sinfatin we are proud to announce that the European Commission, by means of Implementing Decision C(2026) 7475, of 19 October 2026, has <strong>designated rimonabant, the active ingredient in SFT-1, as an orphan drug for the treatment of spinal cord injuries<\/strong> (Community register of orphan medicinal products EU\/3\/26\/3289). The Decision is based on the positive opinion issued on 10 September 2026 by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), in accordance with the criteria laid down in Article 3(1) of Regulation (EC) No 141\/2000 on orphan medicinal products.<\/p><p>Spinal cord injury is a highly complex and rare neurological condition in the European Union, profoundly affecting the quality of life and social participation of both those affected and their caregivers. Our clinical program focuses on improving the walking ability of individuals with spinal cord injury who retain the capacity to walk.<\/p><p>SFT-1 contains a low dose (5 mg) of rimonabant as its active ingredient. Rimonabant is an inverse agonist\/antagonist of CB1 cannabinoid receptors, capable of crossing the blood-brain barrier and acting within the central nervous system (CNS). By blocking the constitutive activity of the CB1 receptor, rimonabant promotes the release of excitatory neurotransmitters and increases the excitability of motor neurons, both cortically and spinally. We expect that this effect may help compensate for the decreased excitability of neurons below the level of spinal cord injury, thereby promoting the activation of a greater number of motor neurons and, consequently, muscle fibers.<\/p><p>The results available to date, including those from the phase 2b clinical trial, RIMOFATSCI-2, indicate that SFT-1 has the potential to improve motor function in people with incomplete thoracolumbar spinal cord injury, meeting a previously unmet therapeutic need.<\/p><p>This designation provides a significant boost to the continued development of SFT-1 for this indication. It grants us access to EMA protocol assistance (specific scientific and regulatory advice for orphan drugs) and allows us, as an SME, to benefit from fee exemption when submitting the marketing authorization application. Once authorized, SFT-1 will be eligible for a period of market exclusivity in the European Union (currently 10 years).<\/p><p>We want to share this achievement with the clinical centers that have accompanied us on this journey, especially with the National Hospital for Paraplegics of Toledo and its Foundation, where this project took its first steps, and with the Guttmann Institute of Barcelona.<\/p><p>We also extend our gratitude and congratulations to the technology centers, organizations, and companies with whom we have worked and continue to collaborate in the development of SFT-1: BIC Gipuzkoa, where our development laboratory is located; Medalchemy, collaborators in the synthesis of the active ingredient; Tecnalia, in the development and analytical validation; Laboratorium Sanitatis, in the manufacture of development batches and the medication for clinical trials; CIDETEC, in the characterization of new formulations; and the Te\u00f3filo Hernando Foundation in conducting clinical trials. And to our partners, especially SAMOS Medical Enterprise and Pharmaceutical Innovation Services, for their support and contribution to the product&#039;s development.<\/p><p>At Sinfatin we continue working to achieve our goal: to obtain marketing authorization for SFT-1 and expand its development to other indications.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-eaf60b9 e-flex e-con-boxed e-con e-parent\" data-id=\"eaf60b9\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-a379332 e-con-full e-flex elementor-invisible e-con e-child\" data-id=\"a379332\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;fadeIn&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6b5b46e elementor-widget elementor-widget-heading\" data-id=\"6b5b46e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Features of Rimonabant<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1245bf1 elementor-widget elementor-widget-text-editor\" data-id=\"1245bf1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<ul><li><strong>Name:<\/strong> Rimonabant.<\/li><li><strong>Therapeutic class:<\/strong> Endocannabinoid type 1 (CB1) receptor antagonist\/inverse agonist.<\/li><li><strong>Route of administration:<\/strong> Oral.<\/li><li><strong>Current status:<\/strong> In clinical development phase for new therapeutic indications.<\/li><li><strong>Known security:<\/strong> We have previous efficacy and tolerability data in humans, which facilitates its repositioning.<\/li><li><strong>Current purpose:<\/strong> To evaluate its effectiveness for the treatment of patients with stroke, spinal cord injury and other pathologies that present fatigue and motor deficits.<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-bd52c5e e-con-full e-flex elementor-invisible e-con e-child\" data-id=\"bd52c5e\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;fadeInRight&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-be32699 e-transform elementor-widget elementor-widget-image\" data-id=\"be32699\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_transform_translateY_effect_hover&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:-10,&quot;sizes&quot;:[]},&quot;_transform_translateX_effect_hover&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;_transform_translateX_effect_hover_laptop&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;_transform_translateX_effect_hover_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;_transform_translateX_effect_hover_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;_transform_translateY_effect_hover_laptop&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;_transform_translateY_effect_hover_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;_transform_translateY_effect_hover_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]}}\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"298\" height=\"210\" src=\"https:\/\/sinfatin.com\/wp-content\/uploads\/2025\/07\/1200px-Rimonabant_svg-removebg-preview.png\" class=\"attachment-large size-large wp-image-212\" alt=\"Clinical development of Rimonabant\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-dcea276 elementor-widget elementor-widget-text-editor\" data-id=\"dcea276\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Chemical structure of SR141716A (Rimonabant)<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-f718c97 #info e-flex e-con-boxed e-con e-parent\" data-id=\"f718c97\" data-element_type=\"container\" data-e-type=\"container\" id=\"#info\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-f7e417b e-con-full e-flex e-con e-child\" data-id=\"f7e417b\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div class=\"elementor-element elementor-element-476cda8 e-con-full e-flex elementor-invisible e-con e-child\" data-id=\"476cda8\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;fadeInLeft&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-bcf6ddd elementor-widget elementor-widget-heading\" data-id=\"bcf6ddd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Stage of development<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4e661b9 elementor-widget elementor-widget-text-editor\" data-id=\"4e661b9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>The rimonabant project in Sinfatin is located at:<\/p><ul><li><strong>Clinical phase<\/strong><br \/>It is currently in the intermediate phase of clinical development, evaluating its efficacy and therapeutic application in phase II and IIb studies.<\/li><li><strong>Priority lines of application:<\/strong><ul><li>Ictus<\/li><li>Spinal cord injury<\/li><li>Post-COVID-19 syndrome<\/li><li>Other possible applications<\/li><\/ul><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-5af8d1d e-con-full e-flex elementor-invisible e-con e-child\" data-id=\"5af8d1d\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;fadeInLeft&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-654c59b elementor-widget elementor-widget-heading\" data-id=\"654c59b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Potential benefits of Rimonabant<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-51c97b4 elementor-widget elementor-widget-text-editor\" data-id=\"51c97b4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<ul><li>Modulation of the endocannabinoid system by increasing excitability in motor neurons<\/li><li>Improvement of motor function after spinal cord injury.<\/li><li>Known safety profile that facilitates its development for new indications.<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-eb2bc37 e-flex e-con-boxed e-con e-parent\" data-id=\"eb2bc37\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-253cf13 elementor-widget elementor-widget-heading\" data-id=\"253cf13\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Pipeline<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d64d2eb elementor-widget elementor-widget-image\" data-id=\"d64d2eb\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t<style>.elementor-element-d64d2eb{display:none !important}<\/style>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-62b6102 elementor-widget elementor-widget-image\" data-id=\"62b6102\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"1610\" height=\"867\" src=\"https:\/\/sinfatin.com\/wp-content\/uploads\/2025\/09\/PIPELINE-RIMO-EN-e1758277569711.png\" class=\"attachment-full size-full wp-image-1355\" alt=\"\" srcset=\"https:\/\/sinfatin.com\/wp-content\/uploads\/2025\/09\/PIPELINE-RIMO-EN-e1758277569711.png 1610w, https:\/\/sinfatin.com\/wp-content\/uploads\/2025\/09\/PIPELINE-RIMO-EN-e1758277569711-768x414.png 768w, https:\/\/sinfatin.com\/wp-content\/uploads\/2025\/09\/PIPELINE-RIMO-EN-e1758277569711-1024x551.png 1024w, https:\/\/sinfatin.com\/wp-content\/uploads\/2025\/09\/PIPELINE-RIMO-EN-e1758277569711-1536x827.png 1536w, https:\/\/sinfatin.com\/wp-content\/uploads\/2025\/09\/PIPELINE-RIMO-EN-e1758277569711-18x10.png 18w\" sizes=\"(max-width: 1610px) 100vw, 1610px\">\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-9e80dec e-flex e-con-boxed e-con e-parent\" data-id=\"9e80dec\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-d8590cd e-con-full e-flex elementor-invisible e-con e-child\" data-id=\"d8590cd\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;fadeIn&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-fee3a02 elementor-widget elementor-widget-heading\" data-id=\"fee3a02\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"> Mechanism of action of Rimonabant<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-eba90b7 elementor-widget elementor-widget-text-editor\" data-id=\"eba90b7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Rimonabant functions as a CB1 receptor antagonist\/inverse agonist, primarily targeting receptors located in the central nervous system.<\/p><p>These receptors are an integral part of the endocannabinoid system, which plays a crucial role in regulating neurotransmission.<\/p><p>Normally, endocannabinoids activate CB1 receptors to inhibit neurotransmitter release. However, when rimonabant blocks these receptors, it increases the release of neurotransmitters, especially glutamate.<\/p><p>This action increases neuronal excitability, which is especially beneficial for improving the functionality of the motor system in people who have deterioration resulting from conditions such as spinal cord injuries or strokes.<\/p><p>If you would like more information about this drug, please contact us.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2f86f21 e-transform elementor-tablet-align-center elementor-widget elementor-widget-button\" data-id=\"2f86f21\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_transform_translateY_effect_hover&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:-10,&quot;sizes&quot;:[]},&quot;_transform_translateX_effect_hover&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;_transform_translateX_effect_hover_laptop&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;_transform_translateX_effect_hover_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;_transform_translateX_effect_hover_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;_transform_translateY_effect_hover_laptop&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;_transform_translateY_effect_hover_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;_transform_translateY_effect_hover_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]}}\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/sinfatin.com\/en\/contact\/?motivo=rimonabant#formulario-contacto\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Request information about Rimonabant<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-b1e975e e-con-full e-flex elementor-invisible e-con e-child\" data-id=\"b1e975e\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;,&quot;animation&quot;:&quot;fadeInRight&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-42bf0de elementor-hidden-tablet elementor-hidden-mobile elementor-widget elementor-widget-image\" data-id=\"42bf0de\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"768\" height=\"1152\" src=\"https:\/\/sinfatin.com\/wp-content\/uploads\/2025\/09\/rimo_OP-768x1152.webp\" class=\"attachment-medium_large size-medium_large wp-image-1204\" alt=\"Clinical development of Rimonabant\" srcset=\"https:\/\/sinfatin.com\/wp-content\/uploads\/2025\/09\/rimo_OP-768x1152.webp 768w, https:\/\/sinfatin.com\/wp-content\/uploads\/2025\/09\/rimo_OP-512x768.webp 512w, https:\/\/sinfatin.com\/wp-content\/uploads\/2025\/09\/rimo_OP-683x1024.webp 683w, https:\/\/sinfatin.com\/wp-content\/uploads\/2025\/09\/rimo_OP-8x12.webp 8w, https:\/\/sinfatin.com\/wp-content\/uploads\/2025\/09\/rimo_OP.webp 1024w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-90cf773 elementor-hidden-desktop elementor-hidden-laptop elementor-widget elementor-widget-image\" data-id=\"90cf773\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"1536\" src=\"https:\/\/sinfatin.com\/wp-content\/uploads\/2025\/09\/rimo_OP.webp\" class=\"attachment-full size-full wp-image-1204\" alt=\"Clinical development of Rimonabant\" srcset=\"https:\/\/sinfatin.com\/wp-content\/uploads\/2025\/09\/rimo_OP.webp 1024w, https:\/\/sinfatin.com\/wp-content\/uploads\/2025\/09\/rimo_OP-512x768.webp 512w, https:\/\/sinfatin.com\/wp-content\/uploads\/2025\/09\/rimo_OP-683x1024.webp 683w, https:\/\/sinfatin.com\/wp-content\/uploads\/2025\/09\/rimo_OP-768x1152.webp 768w, https:\/\/sinfatin.com\/wp-content\/uploads\/2025\/09\/rimo_OP-8x12.webp 8w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-4be39738 e-flex e-con-boxed e-con e-parent\" data-id=\"4be39738\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4b8605ad elementor-widget__width-initial elementor-widget-mobile__width-inherit elementor-widget elementor-widget-heading\" data-id=\"4b8605ad\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">We work to improve the lives of those living with central nervous system disorders by mitigating fatigue due to damage to motor systems.<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-143b6b77 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"143b6b77\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Our commitment is to move toward more effective, safe, and accessible treatments.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5a493727 elementor-align-center e-transform e-transform elementor-widget elementor-widget-button\" data-id=\"5a493727\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_transform_scale_effect_hover&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:1.05,&quot;sizes&quot;:[]},&quot;_transform_scale_effect&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;_transform_scale_effect_laptop&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;_transform_scale_effect_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;_transform_scale_effect_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;_transform_scale_effect_hover_laptop&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;_transform_scale_effect_hover_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;_transform_scale_effect_hover_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]}}\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/sinfatin.com\/en\/contact\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">learn more<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Desarrollo cl\u00ednico de Rimonabant Inicio La Comisi\u00f3n Europea concede la designaci\u00f3n de medicamento hu\u00e9rfano a SFT-1 (rimonabant), de Sinfatin S.L. para el tratamiento de lesiones de la m\u00e9dula espinal En Sinfatin nos enorgullece anunciar que la Comisi\u00f3n Europea, mediante decisi\u00f3n de ejecuci\u00f3n C (2026) 7475, de 19 de octubre de 2026, ha designado rimonabant, el [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-595","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/sinfatin.com\/en\/wp-json\/wp\/v2\/pages\/595","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sinfatin.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/sinfatin.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/sinfatin.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/sinfatin.com\/en\/wp-json\/wp\/v2\/comments?post=595"}],"version-history":[{"count":14,"href":"https:\/\/sinfatin.com\/en\/wp-json\/wp\/v2\/pages\/595\/revisions"}],"predecessor-version":[{"id":1439,"href":"https:\/\/sinfatin.com\/en\/wp-json\/wp\/v2\/pages\/595\/revisions\/1439"}],"wp:attachment":[{"href":"https:\/\/sinfatin.com\/en\/wp-json\/wp\/v2\/media?parent=595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}